# Therapeutic effect and mechanism of different doses of aspirin on preterm delivery in pregnant mice

**Authors:** Xinlan Qu, Xuechun Wu, Xiaomeng Pang, Yuan Fang, Jayonta Bhattacharjee, Jayonta Bhattacharjee, Giovanni Tossetta, Giovanni Tossetta

PMC · DOI: 10.1371/journal.pone.0344041 · 2026-03-05

## TL;DR

This study shows that aspirin can reduce preterm birth in mice by lowering inflammation and oxidative stress, offering potential for clinical use.

## Contribution

The study demonstrates aspirin's therapeutic effect and mechanism in reducing preterm birth in a mouse model.

## Key findings

- Low and high aspirin doses reduced preterm birth rates and increased live births in LPS-treated mice.
- Aspirin suppressed LPS-induced inflammation and oxidative stress markers in maternal and fetal tissues.
- Aspirin improved fetal skeletal development disrupted by LPS-induced inflammation.

## Abstract

Preterm birth is a major cause of perinatal mortality and complications, with inflammation being a key contributing factor. Current treatments, like uterine contraction inhibitors and antibiotics, are unsatisfactory. Aspirin, a cyclooxygenase inhibitor, shows promise in treating infectious preterm labor but has limited in vivo studies and an unclear mechanism.

In this study, a mouse model of infectious preterm birth was established via lipopolysaccharide (LPS) injection, and the aspirin doses used in these animals were converted from the recommended human doses by the body surface area method, with the high-dose and low-dose groups set at 0.78 mg/kg and 0.21 mg/kg, respectively. ELISA detected inflammatory factors TNF-α, IL-1β, IL-6 in serum, amniotic fluid and placenta. WST-8 kit and TBA method measured serum SOD activity and MDA content, respectively. DTNB colorimetric method analyzed glutathione content in liver and placenta. Western blot detected MyD88, IκB, p-IκB and nucleus NF-κB p65 protein expression in uterine tissues.

Results showed the 75 μg/kg LPS group had a 91.7% preterm birth rate and 4.67% stillbirth rate. Low-dose (66.7%) and high-dose (41.6%) aspirin reduced preterm birth and increased live birth rates, with significant intergroup differences (P < 0.05). Aspirin lowered LPS-induced TNF-α, IL-1β, IL-6 in serum, amniotic fluid and placenta, regulated oxidative stress, reversed MyD88/p-IκB overexpression and reduced p65 nuclear translocation. TLR4/NF-κB inhibitors downregulated these factors and nuclear NF-κB p65/p-IκB. Additionally, we found that inflammatory LPS induced abnormal fetal mouse skeletal development (e.g., malformation and deficiency), which was ameliorated by aspirin exposure.

Aspirin may ameliorate preterm birth by up-regulating TLR4/NF-κB pathway, laying theoretical basis for aspirin clinical application in preterm birth.

## Linked entities

- **Proteins:** MYD88 (MYD88 innate immune signal transduction adaptor), Nfkbib (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta), pikB (phosphatidylinositol-4,5-diphosphate 3-kinase)
- **Chemicals:** aspirin (PubChem CID 2244), IL-6 (PubChem CID 165368475), MDA (PubChem CID 1614), glutathione (PubChem CID 124886)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, Tbrs4 (tuberculosis resistance 4) [NCBI Gene 100034832] {aka Trl-4}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Xdh (xanthine dehydrogenase) [NCBI Gene 22436] {aka XO, Xor, Xox-1, Xox1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Cox4i1 (cytochrome c oxidase subunit 4I1) [NCBI Gene 12857] {aka COX, COX IV-1, COXIV, Cox4, Cox4a, IV-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, H3c7 (H3 clustered histone 7) [NCBI Gene 260423] {aka H3.2-221, H3c13, H3c14, H3c15, H3c2, H3c3}, Nfkbib (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta) [NCBI Gene 18036] {aka I(Kappa)B(beta), I-kappa-B-beta, IKB-beta, IKappaBbeta, IkB, IkBb}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, Cgas (cyclic GMP-AMP synthase) [NCBI Gene 214763] {aka E330016A19Rik, Mb21d1}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709]
- **Diseases:** decreased visuospatial abilities (OMIM:313000), cardiovascular metabolic diseases (MESH:D002318), infection (MESH:D007239), neurocognitive impairments (MESH:D019965), Preterm birth (MESH:D047928), bone abnormalities (MESH:D001847), pre-eclampsia (MESH:D011225), thrombosis (MESH:D013927), reperfusion injury (MESH:D015427), Inflammation (MESH:D007249), perinatal death (MESH:D066087), bone absence (MESH:C562753), death (MESH:D003643), occipital dysplasia (MESH:D006259), respiratory distress syndrome (MESH:D012128), sleepiness (MESH:D000077260), costosternal malformations (MESH:C564254), ischemia (MESH:D007511), preterm labor (MESH:D007752), rib malformation (MESH:C537613), infectious (MESH:D003141), necrotizing enterocolitis (MESH:D020345), rib and sternal malformations (MESH:C537489), developmental anomalies (MESH:C566440), stillbirth (MESH:D050497), retinopathy of prematurity (MESH:D012178), skeletal developmental abnormalities (MESH:D009139), Skeletal and malformation (MESH:C535850), inflammatory cytokines (MESH:D000080424), premature delivery (MESH:C536271), periventricular leukomalacia (MESH:D007969)
- **Chemicals:** nitrogen (MESH:D009584), MDA (MESH:D015104), prostaglandin (MESH:D011453), MDA (MESH:D008315), WST-8 (MESH:C476329), H2O2 (MESH:D006861), alizarin red (MESH:C010078), O2 - (MESH:D013481), GD15 (-), formazan (MESH:D005562), BAY 11-7082 (MESH:C434003), glycerin (MESH:D005990), carbol fuchsin (MESH:C006898), DEPC (MESH:D004047), 5-thio-2-nitrobenzoic acid (MESH:C011136), 5,5'-dithiobis-2-nitrobenzoic acid (MESH:D004228), Coomassie blue (MESH:C048139), calcium (MESH:D002118), hydroxyl radicals (MESH:D017665), CO2 (MESH:D002245), GSH (MESH:D005978), Water (MESH:D014867), Asp (MESH:D001241), prostaglandin E2 (MESH:D015232), PGs (MESH:D010715), TBA (MESH:C029684), OH (MESH:C031356), TRIzol (MESH:C411644), potassium hydroxide (MESH:C029943), TAK-242 (MESH:C507035), LPS (MESH:D008070)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Salmonella (genus) [taxon 590], Escherichia coli (E. coli, species) [taxon 562], Sendai virus [taxon 11191], Toxoplasma gondii (species) [taxon 5811], Rodentibacter pneumotropicus (species) [taxon 758], Murine hepatitis virus (no rank) [taxon 11138]
- **Mutations:** C) for 30, S0101S

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962544/full.md

---
Source: https://tomesphere.com/paper/PMC12962544